Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.~* The subject is at least 18 years old.~* The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.~* The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.~* The subject has recovered from clinically significant adverse events (side effects) due to any other medications that were administered prior to randomization.~* The subject has adequate organ and bone marrow function.~* Subjects who are sexually active (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments.~* The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and currently has no evidence of malignancy (unless non-melanoma skin cancer or an early form of cervical cancer).~* Female subjects of childbearing potential must have a negative pregnancy test at screening.~Exclusion Criteria:~* The subject has received prior treatment for their cancer within 4 weeks of randomization (6 weeks for nitrosoureas or mitomycin C).~* The subject has received radiation to ≥ 25 % of bone marrow.~* The subject has received treatment with other investigational agents (unapproved therapies) within 4 weeks of randomization.~* The subject has received treatment with XL184.~* The subject has brain metastases or spinal cord compression, unless completed radiation therapy ≥ 4 weeks prior to randomization and stable without steroid and without anti-convulsant treatment for ≥ 10 days.~* The subject has a history of clinically significant episodes of vomiting blood or a recent history of vomiting \> 2.5 mL (about 1/2 teaspoon) of red blood.~* The subject has serious illness other than cancer.~* The subject is pregnant or breastfeeding.~* The subject has an active infection requiring ongoing treatment.~* The subject is incapable of understanding and complying with the protocol or unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).